Drugs / Fondapariniux
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04406389 | Oct 2020 → Apr 2021 | COVID-19 | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fondapariniux | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04406389 ↗ |
| Route | Subcutaneous | “2.5 mg daily subcutaneously” NCT04406389 ↗ |